索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]费翔,潘珍,程冬冬,等.骨巨细胞瘤治疗研究进展[J].国际骨科学杂志,2024,04:219-223.
点击复制

骨巨细胞瘤治疗研究进展(PDF)

《国际骨科学杂志》[ISSN:1673-7083/CN:31-1952/R]

期数:
2024年04期
页码:
219-223
栏目:
综述
出版日期:
2024-07-20

文章信息/Info

Title:
-
作者:
费翔; 潘珍; 程冬冬; 杨庆诚
200233， 上海交通大学医学院附属第六人民医院骨科?（费翔、程冬冬、杨庆诚）；200050， 上海交通大学医学院附属同仁医院骨科（潘珍）
Author(s):
-
关键词:
骨巨细胞瘤; 手术; 双膦酸盐; 地舒单抗; 靶向治疗
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-7083.2024.04.001
文献标识码:
-
摘要:
骨巨细胞瘤是一种具有局部侵袭性的交界性原发骨肿瘤，其发病机制尚不清楚，特征性表现为溶骨性病变。骨巨细胞瘤具有一定的遗传特征，表现为H3F3A基因突变，该突变成为骨巨细胞瘤的特异性标记物。手术治疗是骨巨细胞瘤的主要治疗方法，包括病灶内刮除术和整块切除术及术后重建。双膦酸盐和地舒单抗等治疗药物的应用打开了骨巨细胞瘤治疗的新局面。靶向治疗也成为骨巨细胞瘤研究领域的新热点。该文就骨巨细胞瘤在手术、放疗、药物及靶向治疗等领域的研究进展进行综述。
Abstract:
-

参考文献/References

[1] Parmeggiani A, Miceli M, Errani C, et al. State of the art and new concepts in giant cell tumor of bone: imaging features and tumor characteristics[J]. Cancers (Basel), 2021, 13(24): 6298.
[2] Niu X, Zhang Q, Hao L, et al. Giant cell tumor of the extremity:retrospective analysis of 621 Chinese patients from one institution[J]. J Bone Joint Surg Am, 2012, 94(5): 461-467.
[3] Noh BJ, Park YK. Giant cell tumor of bone: updated molecular pathogenesis and tumor biology[J]. Hum Pathol, 2018, 81: 1-8.
[4] Basu Mallick A, Chawla SP. Giant cell tumor of bone: an update[J]. Curr Oncol Rep, 2021, 23(5): 51.
[5] Pitsilos C, Givissis P, Papadopoulos P, et al. Treatment of recurrent giant cell tumor of bones: a systematic review[J]. Cancers (Basel), 2023, 15(13): 3287.
[6] Yang Y, Huang Z, Niu X, et al. Clinical characteristics and risk factors analysis of lung metastasis of benign giant cell tumor of bone[J]. J Bone Oncol, 2017, 7: 23-28.
[7] Mavrogenis AF, Igoumenou VG, Megaloikonomos PD, et al. Giant cell tumor of bone revisited[J]. SICOT J, 2017, 3: 54.
[8] Chawla S, Blay JY, Rutkowski P, et al. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study[J]. Lancet Oncol, 2019, 20(12): 1719-1729.
[9] Behjati S, Tarpey PS, Presneau N, et al. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone[J]. Nat Genet, 2013, 45(12): 1479-1482.
[10] Wülling M, Delling G, Kaiser E. The origin of the neoplastic stromal cell in giant cell tumor of bone[J]. Hum Pathol, 2003, 34(10): 983-993.
[11] Cleven AH, H?cker S, Briaire-de Bruijn I, et al. Mutation analysis of h3f3a and h3f3b as a diagnostic tool for giant cell tumor of bone and chondroblastoma[J]. Am J Surg Pathol, 2015, 39(11): 1576-1583.
[12] Scotto di Carlo F, Whyte MP, Gianfrancesco F. The two faces of giant cell tumor of bone[J]. Cancer Lett, 2020, 489: 1-8.
[13] Lutsik P, Baude A, Mancarella D, et al. Globally altered epigenetic landscape and delayed osteogenic differentiation in H3.3-G34W-mutant giant cell tumor of bone[J]. Nat Commun, 2020, 11(1): 5414.
[14] Fellenberg J, S?hr H, Mancarella D, et al. Knock-down of oncohistone H3F3A-G34W counteracts the neoplastic phenotype of giant cell tumor of bone derived stromal cells[J]. Cancer Lett, 2019, 448: 61-69.
[15] Yamamoto H, Iwasaki T, Yamada Y, et al. Diagnostic utility of histone H3.3 G34W, G34R, and G34V mutant-specific antibodies for giant cell tumors of bone[J]. Hum Pathol, 2018, 73: 41-50.
[16] van der Heijden L, Dijkstra PD, van de Sande MA, et al. The clinical approach toward giant cell tumor of bone[J]. Oncologist, 2014, 19(5):550-561.
[17] Wang Q, Zhang Y, Zhang E, et al. A multiparametric method based on clinical and CT-based radiomics to predict the expression of p53 and VEGF in patients with spinal giant cell tumor of bone[J]. Front Oncol, 2022, 12: 894696.
[18] Yue J, Sun W, Li S. Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: a randomized clinical trial[J]. J Bone Oncol, 2022, 35: 100441.
[19] van der Heijden L, Lipplaa A, van Langevelde K, et al. Updated concepts in treatment of giant cell tumor of bone[J]. Curr Opin Oncol, 2022, 34(4): 371-378.
[20] Thomas DM, Skubitz KM. Giant cell tumour of bone[J]. Curr Opin Oncol, 2009, 21(4): 338-344.
[21] Balke M, Schremper L, Gebert C, et al. Giant cell tumor of bone:treatment and outcome of 214 cases[J]. J Cancer Res Clin Oncol, 2008, 134(9): 969-978.
[22] Chadha M, Arora SS, Singh AP, et al. Autogenous non-vascularized fibula for treatment of giant cell tumor of distal end radius[J]. Arch Orthop Trauma Surg, 2010, 130(12): 1467-1473.
[23] Vidal L, Kampleitner C, Brennan M, et al. Reconstruction of large skeletal defects: current clinical therapeutic strategies and future directions using 3D printing[J]. Front Bioeng Biotechnol, 2020, 8: 61.
[24] Vaishya R, Pokhrel A, Agarwal AK, et al. Current status of bone cementing and bone grafting for giant cell tumour of bone: a systemic review[J]. Ann R Coll Surg Engl, 2019, 101(2): 79-85.
[25] Chobpenthai T, Poosiripinyo T, Warakul C. Reconstruction after en bloc resection of a distal radius tumor. An updated and concise review[J]. Orthop Res Rev, 2023, 15: 151-164.
[26] Kuptniratsaikul V, Luangjarmekorn P, Charoenlap C, et al. Anatomic 3D-printed endoprosthetic with multiligament reconstruction after en bloc resection in giant cell tumor of distal radius[J]. J Am Acad Orthop Surg Glob Res Rev, 2021, 5(2): e20.00178.
[27] Shi W, Indelicato DJ, Reith J, et al. Radiotherapy in the management of giant cell tumor of bone[J]. Am J Clin Oncol, 2013, 36(5): 505-508.
[28] Mendenhall WM, Zlotecki RA, Scarborough MT, et al. Giant cell tumor of bone[J]. Am J Clin Oncol, 2006, 29(1): 96-99.
[29] Thomas DM. RANKL, denosumab, and giant cell tumor of bone[J]. Curr Opin Oncol, 2012, 24(4): 397-403.
[30] Rock MG, Sim FH, Unni KK, et al. Secondary malignant giant-cell tumor of bone. Clinicopathological assessment of nineteen patients[J]. J Bone Joint Surg Am, 1986, 68(7): 1073-1079.
[31] Turcotte RE. Giant cell tumor of bone[J]. Orthop Clin North Am, 2006, 37(1): 35-51.
[32] Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice[J]. Mayo Clin Proc, 2008, 83(9):1032-1045.
[33] Kavanagh KL, Guo K, Dunford JE, et al. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs[J]. Proc Natl Acad Sci U S A, 2006, 103(20): 7829-7834.
[34] Cheng YY, Huang L, Lee KM, et al. Bisphosphonates induce apoptosis of stromal tumor cells in giant cell tumor of bone[J]. Calcif Tissue Int, 2004, 75(1): 71-77.
[35] Shi M, Chen L, Wang Y, et al. Effect of bisphosphonates on local recurrence of giant cell tumor of bone: a meta-analysis[J]. Cancer Manag Res, 2019, 11: 669-680.
[36] Kundu ZS, Sen R, Dhiman A, et al. Effect of intravenous zoledronic acid on histopathology and recurrence after extended curettage in giant cell tumors of bone: a comparative prospective study[J]. Indian J Orthop, 2018, 52(1): 45-50.
[37] Palmerini E, Chawla NS, Ferrari S, et al. Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): for how long?[J]. Eur J Cancer, 2017, 76: 118-124.
[38] Rutkowski P, Gaston L, Borkowska A, et al. Denosumab treatment of inoperable or locally advanced giant cell tumor of bone - Multicenter analysis outside clinical trial[J]. Eur J Surg Oncol, 2018, 44(9): 1384-1390.
[39] Branstetter DG, Nelson SD, Manivel JC, et al. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone[J]. Clin Cancer Res, 2012, 18(16): 4415-4424.
[40] Mak IW, Evaniew N, Popovic S, et al. A translational study of the neoplastic cells of giant cell tumor of bone following neoadjuvant denosumab[J]. J Bone Joint Surg Am, 2014, 96(15): e127.
[41] Palmerini E, Staals EL, Jones LB, et al. Role of (Neo)adjuvant denosumab for giant cell tumor of bone[J]. Curr Treat Options Oncol, 2020, 21(8): 68.
[42] Kimura A, Toda Y, Matsumoto Y, et al. Nuclear β-catenin translocation plays a key role in osteoblast differentiation of giant cell tumor of bone[J]. Sci Rep, 2022, 12(1): 13438.
[43] Traub F, Singh J, Dickson BC, et al. Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone[J]. Eur J Cancer, 2016, 59: 1-12.
[44] Kerr DA, Brcic I, Diaz-Perez JA, et al. Immunohistochemical characterization of giant cell tumor of bone treated with denosumab:support for osteoblastic differentiation[J]. Am J Surg Pathol, 2021, 45(1): 93-100.
[45] Mahdal M, Neradil J, Mudry P, et al. New target for precision medicine treatment of giant-cell tumor of bone: sunitinib is effective in the treatment of neoplastic stromal cells with activated PDGFRβ signaling[J]. Cancers (Basel), 2021, 13(14): 3543.
[46] Ni LY, Zhao JD, Lu YH, et al. MicroRNA-30c suppressed giant-cell tumor of bone cell metastasis and growth via targeting HOXA1[J]. Eur Rev Med Pharmacol Sci, 2017, 21(21): 4819-4827.
[47] Sang S, Zhang Z, Qin S, et al. MicroRNA-16-5p inhibits osteoclastogenesis in giant cell tumor of bone[J]. Biomed Res Int, 2017, 2017: 3173547.
[48] Herr I, S?hr H, Zhao Z, et al. MiR-127 and miR-376a act as tumor suppressors by in vivo targeting of COA1 and PDIA6 in giant cell tumor of bone[J]. Cancer Lett, 2017, 409: 49-55.
[49] Chen F, Wang S, Wei Y, et al. Norcantharidin modulates the miR-30a/Metadherin/AKT signaling axis to suppress proliferation and metastasis of stromal tumor cells in giant cell tumor of bone[J]. Biomed Pharmacother, 2018, 103: 1092-1100.
[50] Jiang ZY, Jiang JJ, Ma YS, et al. Downregulation of miR-223 and miR-19a induces differentiation and promotes recruitment of osteoclast cells in giant-cell tumor of the bone via the Runx2/TWIST-RANK/RANKL pathway[J]. Biochem Biophys Res Commun, 2018, 505(4): 1003-1009.
[51] Kushlinskii NE, Alferov AA, Timofeev YS, et al. Key immune checkpoint PD-1/PD-L1 signaling pathway components in the blood serum from patients with bone tumors[J]. Bull Exp Biol Med, 2020, 170(1): 64-68.
[52] Metovic J, Annaratone L, Linari A, et al. Prognostic role of PD-L1 and immune-related gene expression profiles in giant cell tumors of bone[J]. Cancer Immunol Immunother, 2020, 69(9): 1905-1916.
[53] Toda Y, Kohashi K, Yamamoto H, et al. Tumor microenvironment in giant cell tumor of bone: evaluation of PD-L1 expression and SIRPα infiltration after denosumab treatment[J]. Sci Rep, 2021, 11(1):14821.
[54] Wan Z, Lee C, Yuan S, et al. Can p63 serve as a biomarker for diagnosing giant cell tumor of bone? A systematic review and meta-analysis[J]. Sao Paulo Med J, 2020, 138(5): 393-399.

备注/Memo

备注/Memo:
基金项目：国家自然科学基金（82173343）、国家自然科学基金?（81872182）
通信作者：杨庆诚 E-mail: tjyqc@163.com
更新日期/Last Update: 2024-07-20